Compare

NextCure, Inc. vs Actinium Pharmaceuticals, Inc. vs Vistagen Therapeutics, Inc. vs Akari Therapeutics Plc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearNextCure, Inc.
NXTC
Actinium Pharmaceuticals, Inc.
ATNM
Vistagen Therapeutics, Inc.
VTGN
Akari Therapeutics Plc
AKTX
Year ended2025-12-312025-12-312026-03-312025-12-31
Revenuen/a$90.0K$1.27Mn/a
Revenue growth (YoY)n/an/a+161.1%n/a
Gross marginn/an/an/an/a
Operating marginn/an/mn/mn/a
Net marginn/an/mn/mn/a
Net income-$55.84M-$33.89M-$69.69M-$17.30M
EPS (Diluted)-$19.65-$1.09-$1.83$0.00
Operating cash flow-$49.61M-$24.58M-$66.44M-$10.57M
Free cash flown/a-$24.68Mn/an/a
Cash & equivalents$25.98M$48.00M$30.79M$0
Total assets$50.18M$51.77M$48.56M$47.89M
Total liabilities$15.24M$43.94M$13.04M$19.56M
Shareholders' equity$34.94M$7.83M$35.52M$28.33M
Return on year-end equity-159.8%-432.6%-196.2%-61.1%
Shares outstanding3.51M31.20Mn/a90.54B

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearNextCure, Inc.Actinium Pharmaceuticals, Inc.Vistagen Therapeutics, Inc.Akari Therapeutics Plc
Latest$22.38M
Ended 2020-12-31
$90.0K
Ended 2025-12-31
$1.27M
Ended 2026-03-31
n/a
1 year earlier$6.35M
Ended 2019-12-31
n/a$486.0K
Ended 2025-03-31
n/a
2 years earliern/a$81.0K
Ended 2023-12-31
$1.06M
Ended 2024-03-31
n/a
3 years earliern/a$1.03M
Ended 2022-12-31
n/an/a
4 years earliern/a$1.14M
Ended 2021-12-31
$1.11M
Ended 2022-03-31
n/a